These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 10063994

  • 1. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty.
    Vuillemenot A, Schiele F, Meneveau N, Claudel S, Donat F, Fontecave S, Cariou R, Samama MM, Bassand JP.
    Thromb Haemost; 1999 Feb; 81(2):214-20. PubMed ID: 10063994
    [Abstract] [Full Text] [Related]

  • 2. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK, Mahrholdt H, Schröder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR.
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [Abstract] [Full Text] [Related]

  • 3. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G, Rupprecht HJ, Luz M, Terres W, Schindel F, Friesen HJ, Heinrichs H, Jessel A, Meyer J, Prellwitz W.
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [Abstract] [Full Text] [Related]

  • 4. Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial.
    Heintzen MP, Heidland UE, Klimek WJ, Leschke M, Kelm M, Schwartzkopff B, Vester EG, Michel CJ, Strauer BE.
    Heart; 2000 May; 83(5):551-6. PubMed ID: 10768906
    [Abstract] [Full Text] [Related]

  • 5. [Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
    Heintzen MP, Heidland UE, Klimek WJ, Michel CJ, Kelm M, Leschke M, Schwartzkopff B, Vester EG, Strauer BE.
    Z Kardiol; 1997 Dec; 86(12):961-7. PubMed ID: 9499493
    [Abstract] [Full Text] [Related]

  • 6. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L, Blombäck M, Egberg N, Olsson A, Svane B, Velander M.
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [Abstract] [Full Text] [Related]

  • 7. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.
    Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, Michels R, Vahanian A, Vanderheyden M, Rupprecht HJ, Van de Werf F, PENTALYSE investigators.
    Eur Heart J; 2001 Sep; 22(18):1716-24. PubMed ID: 11511121
    [Abstract] [Full Text] [Related]

  • 8. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
    Bernat A, Savi P, Lale A, Hoffmann P, Herbert JM.
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):573-9. PubMed ID: 10218727
    [Abstract] [Full Text] [Related]

  • 9. Prevention and management of thrombotic complications during coronary interventions. Combination therapy with antithrombins, antiplatelets, and/or thrombolytics: risks and benefits.
    Neuhaus KL, Zeymer U.
    Eur Heart J; 1995 Nov; 16 Suppl L():63-7. PubMed ID: 8869021
    [Abstract] [Full Text] [Related]

  • 10. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 11. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.
    Pislaru SV, Pislaru C, Zhu X, Arnout J, Stassen T, Vanhove P, Herbert JM, Meuleman DG, Van de Werf F.
    Thromb Haemost; 1998 Jun; 79(6):1130-5. PubMed ID: 9657437
    [Abstract] [Full Text] [Related]

  • 12. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
    Schächinger V, Allert M, Kasper W, Just H, Vach W, Zeiher AM.
    Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
    [Abstract] [Full Text] [Related]

  • 13. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
    Suzuki S, Matsuo T, Kobayashi H, Matsuo M, Shimamo C, Koide M, Sakamoto S.
    Thromb Res; 2000 May 15; 98(4):269-79. PubMed ID: 10822073
    [Abstract] [Full Text] [Related]

  • 14. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Semin Thromb Hemost; 2008 Feb 15; 34(1):58-73. PubMed ID: 18393143
    [Abstract] [Full Text] [Related]

  • 15. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ, Wilson JM, Diez J.
    Minerva Cardioangiol; 2007 Oct 15; 55(5):529-56. PubMed ID: 17912162
    [Abstract] [Full Text] [Related]

  • 16. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR, Kelly SA, Allan RM, Giles RW, McCredie M, Walsh WF.
    Cathet Cardiovasc Diagn; 1996 Feb 15; 37(2):145-50. PubMed ID: 8808069
    [Abstract] [Full Text] [Related]

  • 17. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.
    Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, Bossi IM, Mannucci PM.
    J Am Coll Cardiol; 1997 Jan 15; 29(1):13-20. PubMed ID: 8996289
    [Abstract] [Full Text] [Related]

  • 18. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty.
    Gulba DC, Daniel WG, Simon R, Jost S, Barthels M, Amende I, Rafflenbeul W, Lichtlen PR.
    J Am Coll Cardiol; 1990 Sep 15; 16(3):563-8. PubMed ID: 2117619
    [Abstract] [Full Text] [Related]

  • 19. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun 15; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

  • 20. Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation.
    Lehmann KG, Gonzales E, Tri BD, Vaziri ND.
    Am Heart J; 1999 Feb 15; 137(2):274-83. PubMed ID: 9924161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.